Navigation Links
Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
Date:5/7/2009

PITTSBURGH, May 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Mycophenolate Mofetil Tablets, 500 mg, and Mycophenolate Mofetil Capsules, 250 mg.

Mycophenolate Mofetil is the generic name for Roche's CellCept(R), which is indicated for the prevention of organ rejection in patients receiving kidney, heart or liver transplants. CellCept Tablets, 500 mg, and CellCept Capsules, 250 mg, had annual U.S. sales of approximately $680 million and $367 million, respectively, for the 12 months ending March 31, 2009, according to IMS Health. Mylan has commenced shipping both products.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
4. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
5. Mylan Announces Clarinex(R) Settlement Agreement
6. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
7. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
8. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
9. Mylan Announces Transition of Chief Financial Officer
10. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
11. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , ... June 28, 2017 , ... ... is pleased to announce that a two year study conducted by the University ... Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part of ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with ... lodgings for families with children receiving treatment in nearby hospitals. , Ronald McDonald ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a ... assets on the Ethereum blockchain, has released their technical specifications . , 2017 ... has been little systematic approach for determining which offerings will garner the greatest ROI. ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and Widex ... Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate hearing ... today’s savvy consumer, and the latest in hearing technology. At the event, EarQ ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is looking ... studies guidebook. This guidebook offers an excellent branding and exposure opportunity for the ... studies and how-to’s that fall into the following categories:, , ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... June 19, 2017  Researchers from DRUGSCAN ® ... will host a live, complimentary webinar titled, "Untangling methods ... to the real world" on Wednesday June 28, 2017 ... This webinar will feature interviews with recreational and ... the manipulation techniques abusers use to prepare opioid tablets ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
Breaking Medicine Technology: